Clinical Characteristics |
No. of Patients (%) |
No. of Patients
(%) |
|
neoadjuvant treatment group
(n=9)
|
adjuvant treatment group
(n=16)
|
Gender |
|
|
Male |
6 (66.7) |
6 (37.5) |
Female |
3 (33.3) |
10(62.5) |
Age:Median [range], y |
57[34-67] |
58[42-72] |
Weight: Median [range], kg |
67[52-90] |
61.5[45-85] |
Height:Median[range],cm |
168[152-177] |
165[150-178] |
Primary site |
|
|
Stomach |
7(77.8) |
11(68.8) |
Small intestine |
2(22.2) |
5(31.2) |
Kinase mutation |
|
|
c-kit 11 mutation |
7(77.8) |
10(62.5) |
c-kit 9 mutation |
- |
1(6.3) |
unknown |
2(22.2) |
5(31.2) |
Dosage |
|
|
200 mg/d |
- |
1(6.3) |
300 mg/d |
- |
4(25.0) |
400 mg/d |
9(100) |
9(56.2) |
600 mg/d |
- |
2(12.5) |
Medication duration:Median[range],d |
110[30-300] |
39[8-420] |